GE HealthCare strengthens AI offerings with Diagnoly collaboration to advance AI-enabled fetal ultrasound

• Agreement aims to integrate Diagnoly’s Fetoly™ solution within Voluson™ ultrasound systems
• Fetoly’s real-time AI solution is intended to bring advanced cardiac and brain analysis to Voluson users for more comprehensive fetal examinations
• Diagnoly’s Fetoly solution now available in the U.S. and Europe through the Voluson Solution Store, the first digital marketplace for women’s health ultrasound

GE HealthCare (Nasdaq: GEHC) today announced a collaboration with Diagnoly, a pioneering DeepTech company specializing in AI-driven prenatal screening, to advance the use of artificial intelligence in fetal ultrasound assessments. Through this agreement, the two companies will accelerate the integration of Diagnoly’s Fetoly™ solution within GE HealthCare’s Voluson™ women’s health ultrasound systems.

Ultrasound plays a vital role throughout pregnancy, offering clinicians insights into fetal growth, development, and potential congenital conditions. However, factors such as high-fetal movement, increased maternal abdominal wall thickness, and operator variability can create barriers to conducting consistent, high-quality examinations.[i] Integrating advanced technology—such as AI-enabled tools—into ultrasound can help clinicians streamline examinations, reduce workload, and enhance consistency and accuracy of fetal assessments.

“AI is redefining what’s possible in healthcare, and GE HealthCare is at the forefront of this movement, as an industry leader bringing AI-powered innovations to clinicians,” said Gerald Seifriedsberger, General Manager, Women’s Health Ultrasound, GE HealthCare. “This collaboration with Diagnoly further expands our ability to integrate advanced AI-based screening support into Voluson ultrasound, helping elevate care for women and their babies.”

Fetoly is a real-time AI solution designed to deliver comprehensive and standardized fetal ultrasound examinations, aligned with International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guidelines. The solution aims to provide clinicians with AI-powered clinical diagnostic support for fetal heart and brain analysis while continuously verifying exam completeness and quality criteria in real time. This capability is expected to further enhance the Voluson portfolio, supporting clinicians in delivering optimal care.

“Obstetric ultrasound remains one of the most powerful, but also complex imaging techniques. As a result, up to 50% of fetal abnormalities remain undetected during pregnancy.[ii] At Diagnoly, we believe AI can play a transformative role in making high‑quality screening more accurate, accessible and consistent,” said Ivan Voznyuk, Co-Founder and CEO of Diagnoly. “The integration of Fetoly into trusted Voluson ultrasound systems reflects our shared commitment to supporting clinicians in real-time with tools that can help improve maternal and fetal outcomes.”

Fetoly is U.S. Food and Drug Administration 510(k) cleared and CE marked. The AI application is available as a free trial on the Voluson Solution Store and other major mobile app platforms.

Voluson ultrasound systems and Fetoly will be showcased at the 2026 Society for Maternal-Fetal Medicine (SMFM) Pregnancy Meeting on February 8-13 in Las Vegas. For more information, visit:
www.volusonclub.net/events/smfm-2026.